NYSE: MDT
Medtronic PLC Stock

$84.01-0.13 (-0.15%)
Updated Dec 6, 2024
MDT Price
$84.01
Fair Value Price
N/A
Market Cap
$107.72B
52 Week Low
$75.96
52 Week High
$92.68
P/E
25.53x
P/B
2.22x
P/S
3.52x
PEG
1.05x
Dividend Yield
3.31%
Revenue
$33.00B
Earnings
$4.29B
Gross Margin
65%
Operating Margin
17.84%
Profit Margin
13%
Debt to Equity
0.85
Operating Cash Flow
$7B
Beta
0.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

MDT Overview

Medtronic plc manufactures device-based medical therapies. The company's Cardiovascular segment offers implantable cardiac pacemakers, cardioverter defibrillators, cardiac resynchronization therapy devices, cardiac ablation products, insertable cardiac monitor systems, TYRX products, and remote monitoring and patient-centered software. Its Medical Surgical segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence, and robotic-assisted surgery products. Medtronic was founded in 1949 and is headquartered in Dublin, Ireland.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine MDT's potential to beat the market

BBuy
  • Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More

Zen Rating Component Grades

B
Value
C
Growth
C
Momentum
C
Sentiment
A
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
D
MDT
Ranked
#31 of 127

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$28.71A
$11.68A
$49.71A
View Top Medical Device Stocks

Be the first to know about important MDT news, forecast changes, insider trades & much more!

MDT News

Overview

Due Diligence Score

Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MDT scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MDT ($84.01) is trading above its intrinsic value of $47.02, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MDT is good value based on its earnings relative to its share price (25.53x), compared to the US market average (29.86x)
P/E vs Market Valuation
MDT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more MDT due diligence checks available for Premium users.

Valuation

MDT price to earnings (PE)

For valuing profitable companies with steady earnings

Company
25.53x
Industry
36.83x
Market
29.86x
MDT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
MDT is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

MDT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.22x
Industry
4.05x
MDT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MDT price to earnings growth (PEG)

For valuing profitable companies with growth potential

MDT is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

MDT's financial health

Profit margin

Revenue
$8.4B
Net Income
$1.3B
Profit Margin
15.1%
MDT's Earnings (EBIT) of $5.89B... subscribe to Premium to read more.
Interest Coverage Financials
MDT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$90.0B
Liabilities
$41.3B
Debt to equity
0.85
MDT's short-term assets ($22.44B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MDT's long-term liabilities ($29.13B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MDT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MDT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$958.0M
Investing
-$345.0M
Financing
-$534.0M
MDT's operating cash flow ($7.20B)... subscribe to Premium to read more.
Debt Coverage Financials

MDT vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
MDTB$107.72B-0.15%25.53x2.22x
BSXB$132.75B-0.51%73.83x6.41x
SYKB$146.78B+0.67%40.83x7.28x
EWC$42.19B-1.24%10.31x4.42x
DXCMC$30.36B-1.52%44.67x15.34x

Medtronic Stock FAQ

What is Medtronic's quote symbol?

(NYSE: MDT) Medtronic trades on the NYSE under the ticker symbol MDT. Medtronic stock quotes can also be displayed as NYSE: MDT.

If you're new to stock investing, here's how to buy Medtronic stock.

What is the 52 week high and low for Medtronic (NYSE: MDT)?

(NYSE: MDT) Medtronic's 52-week high was $92.68, and its 52-week low was $75.96. It is currently -9.35% from its 52-week high and 10.6% from its 52-week low.

How much is Medtronic stock worth today?

(NYSE: MDT) Medtronic currently has 1,282,285,681 outstanding shares. With Medtronic stock trading at $84.01 per share, the total value of Medtronic stock (market capitalization) is $107.72B.

Medtronic stock was originally listed at a price of $26.25 in Dec 31, 1997. If you had invested in Medtronic stock at $26.25, your return over the last 26 years would have been 220.04%, for an annualized return of 4.58% (not including any dividends or dividend reinvestments).

How much is Medtronic's stock price per share?

(NYSE: MDT) Medtronic stock price per share is $84.01 today (as of Dec 6, 2024).

What is Medtronic's Market Cap?

(NYSE: MDT) Medtronic's market cap is $107.72B, as of Dec 9, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Medtronic's market cap is calculated by multiplying MDT's current stock price of $84.01 by MDT's total outstanding shares of 1,282,285,681.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.